王博輝李岳駿Yueh-Chun Lee醫學研究所2026-10-299999-12-312018https://handle.ncl.edu.tw/11296/29c628https://scholars.csmu.edu.tw/handle/123456789/36387研究背景與目的:口腔癌是頭頸癌的一種,在台灣為排名第五位的癌症。人類癌症由具有異質特性。癌症幹細胞為少部分具有自我更新與生長分化成腫瘤潛力,類似幹細胞特性,能抵抗化學藥物與放射線治療,以及有轉移的能力。在頭頸癌癌症細胞中,已經證實癌症幹細胞的存在。第一型纖維蛋白溶酶原活化抑制物(Plasminogen activator inhibitor-1,PAI-1)是屬於血栓形成的一個相關因子,其作用為不可逆地抑制組織纖維蛋白溶酶原活化物(Tissue plasminogen activator,tPA)和尿激酶型纖溶酶原活化物(Urokinase - type plasminogen activator,uPA)活化纖維蛋白溶酶原的活性。以往研究觀察到PAI-1會抑制凋亡、促進血管新生、腫瘤細胞的爬行(Migration)和侵襲(Invasion),而導致腫瘤的轉移,但是其詳細分子機制還不是很清楚。由分析美國National Cancer Institute(NCI)及National Human Genome Research Institute(NHGRI)建立的癌症基因體圖譜TCGA(The Cancer Genome Atlas)發現,在預後差的扁平細胞口腔癌患者,PAI-1基因(mRNA)表現量高。本研究主要目的為了解PAI-1作用在癌症幹細胞的分子機制,以及抑制PAI-1活性是否進而能抑制口腔癌幹細胞的活性。研究方法:利用PAI-1抑制劑 Tiplaxtinin(PAI-039),與短片段RNA干擾技術了解PAI-1對於口腔癌症幹細胞的維持與致癌性是否扮演角色。癌症幹細胞活性分析實驗經球體培養法,進行西方墨點法,定量聚合酶連鎖反應與螢光素酶報導基因試驗,研究PAI-039的作用與如何調控sex-determining region Y-box 2(Sox2)的表現。研究結果:經由PAI-1特異性短片段RNA下調PAI-1表現,同時觀察到Sox2或Nanog mRNA 表現受到抑制,以及減少nestin、Sox2或Nanog蛋白質的表現,並降低口腔癌症幹細胞的自我更新能力,且增強了放射的敏感性。我們進一步發現,PAI-1 抑制劑 Tiplaxtinin(PAI-039)可下調Sox2基因的核心啟動子或SRR2增強子的活性,進而抑制口腔癌症幹細胞Sox2的mRNA的表現。結論:透過此研究,提供證據證實PAI-1的抑制物Tiplaxtinin(PAI-039)與特異性短片段RNA,確實能抑制PAI-1表現能進而抑制口腔癌幹細胞的自我更新活性,與增強了放射的敏感性,以及清楚的了解其分子機制為轉錄下調Sox2基因,抑制Sox2的表現有關。此研究結果,Tiplaxtinin(PAI-039),未來對於口腔扁平細胞癌的治療,具有相當潛力作為研發為合併放射線治療的藥物。Objective:Oral cavities cancer is one of Head and neck cancers and is ranked fifth of all cancers in the in Taiwan. Human cancer cells consists of heterogeneous properties. Tmor-initiating cells (TICs) are a small population of tumor cells to have stem-like properties, have been shown to participate in self-renew, tumor initiation, resistance to chemo- or radioatherapy, and have the ability to metastasize. In head and neck cancer, the presence of TICs has been confirmed. Plasminogen activator inhibitor-1 (PAI-1) is a related factor of thrombosis, which acts to irreversibly inhibit tissue plasminogen activator (Tissue plasminogen activator, tPA) and Urokinase-type plasminogen activator (uPA). Previous studies have observed that PAI-1 inhibit apoptosis, promotes angiogenesis, tumor cell migration and invasion, leading to metastasis, but the detailed mechanism remains unclear. The higher expression of PAI-1 gene (mRNA) was found in patients with poor prognosis of squamous cell oral cancer by analyzing the cancer TCGA (The Cancer Genome Atlas) which established by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). The main purpose of this study is to delineate the mechanisms of the action that PAI-1 exerts on the TICs of head and neck cancers (HN-TICs) and wheather PAI-1 inhibition can reduce the biologic activity of HN-TICs.Methods and Materials:Tiplaxtinin (PAI-039), a specific inhibitor of PAI-1, and PAI-1 specific siRNA were used to examine the role of PAI-1 in self-renewal property of HN-TICs by tumorsphere formation. Western blot, real-time PCR and luciferase based reporter assay was used to study the effect of PAI-039 in regulation of the sex-determining region Y-box 2 (Sox2) expression.Results:The reduction of Sox2 or Nanog mRNA expression, as well as the reduced expression of PAI-1、Sox2 and Nanog proteins was observed after the down-regulation of PAI-1 by PAI-1-specific siRNA oligos in oral cancer cells. Inhibition of PAI-1 expression displayed the activities in reduction of self-renewal and radioresistance properties of HN-TICs. We also found that PAI-039 reduced Sox2 mRNA expression by decreasing the activity of core promoter and enhancer of Sox2 gene (SRR2). Conclusion:This study demonstrate that the inhibition of PAI-1 by PAI-039 or siRNA mediated gene silencing reduces the self-renewal capability and increases the radiosensitivity of HN-TICs. The TIC targeting effect of PAI-039 is suggested to be associated with the transcriptional downregulation of Sox2 expression. The inhibition of PAI-1 may be considered to be a therapeutic strategy in targeting TICs in head and neck squamous carcinoma.sex-determining region Y-box 2(Sox2)口腔癌原活化抑制物第一型纖維蛋白溶酶癌症幹細胞Tiplaxtinin (PAI-039)head and neck cancerstumor-initiating cellstiplaxtinin (PAI-039)plasminogen activator inhibitor-1 (PAI-1)以第一型纖維蛋白溶酶原活化抑制物為標靶降低口腔癌症幹細胞活性之研究thesis